Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 6;35:74. doi: 10.1186/s13046-016-0353-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© El-Shemi et al. 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 4 — In vivo antitumor effects of Ad-ΔB and Ad-ΔB/TRAIL+Ad-ΔB/IL-12 on an orthotopic transplanted mouse model of human HCC. The model was induced by intrahepatic implantation of 2 × 10⁶ human Hep3B/fluc cells into the left liver lobes of mice in athymic nude mice. Positive HCC-bearing mice were thereafter randomized into three groups (n = 10/group) and through their tail veins they were treated with: PBS alone (Group 1), Ad-ΔB (Group 2), and Ad-ΔB/TRAIL+Ad-ΔB/IL-12 (Group 3) at a dosage regimen of 1 × 10¹⁰ VP in 200 μL PBS of each virus; repeated three times every other day. Next, the mice were monitored and photographed (a) weekly by in vivo bioluminescence imaging to determine the pattern of tumor response to the subjected treatments (b) until the end of study (day 14 post-the last treatment dose)